EmergingMed® is the leading innovator in clinical trial enrollment optimization. The Company provides services for patients that raise awareness and facilitate access to clinical trials. These patient-focused services are part of the broader solution EmergingMed hosts for clinical trial sponsors and investigators to manage the complexities of patient identification, recruitment and retention.. The company's broader vision is to accelerate the discovery of new and better treatments for people with serious and life threatening medical conditions.
EmergingMed's mission is to accelerate the discovery of new and better treatments for people with serious and life threatening medical conditions. Since 2000, the Company’s focus has been the creation of patient-centric tools and services that quickly and accurately connect patients and health care providers to clinical trials testing new therapies in development. EmergingMed is committed to getting the right information to the right person at the right time—always ensuring that information is presented in context and readily actionable.
Our commitment to privacy and security is uncompromising and guides every decision we make. We will never sell or share your personal information. All information submitted to EmergingMed is password protected, confidential and secure. Please read our
Our Patented Clinical Trial Matching Service
EmergingMed received a patent on its System and Method for Matching Patients to Clinical Trials (US Patent No. 7,711,580 B2) in May of 2010. This matching system shortens the clinical trial search process from weeks to minutes, helping users identify clinical trials with eligibility criteria that match a patient’s specific diagnosis, stage, symptoms, and treatment history.
EmergingMed was founded in January 2000 after months of interviews with patients, advocates, caregivers and researchers who helped us understand the barriers, misperceptions, and logistical challenges associated with finding relevant clinical trials and making informed treatment decisions. The EmergingMed.com website and Clinical Trial Navigation Service launched in October 2000. As of November 2014, we have facilitated clinical trial searches for nearly 200,000 cancer patients and 100,000 patients with other serious and life threatening conditions.
EmergingMed's management team has proven that it is adept at innovating as well as scaling solutions to help bring new therapies to market while empowering patients to make more informed treatment decisions.
Our Collaborations with Patient Advocacy Organizations
EmergingMed hosts privately branded Clinical Trial Navigation Services for advocacy groups who want to bring unbiased, actionable clinical trial opportunities to their constituents. EmergingMed also collaborates with patient advocates on education and outreach programs to raise awareness of clinical trials among targeted groups. These clinical trial call-to-action campaigns encourage participants to engage clinical trial matching and referral services and register to receive updates when new clinical trials become available that match a person’s specific clinical and genomic profile.
How We Get Paid
EmergingMed's clinical trial matching, referral, and navigation services are provided free of charge to patients and physicians searching for clinical trials. EmergingMed receives monthly subscription fees for processing phone-based and/or web-based clinical trial inquiries on behalf of other organizations (e.g., patient advocacy groups, pharmaceutical and biotechnology companies, trial sites and research networks, and diagnostic companies). EmergingMed is never paid for referring or enrolling a patient in a trial.
EmergingMed is a private company owned and operated by Final Four Health Solutions, LLC, a family-owned organization dedicated to accelerating the development of new and better treatments for people with serious and life threatening conditions. EmergingMed and FFHS' are headquartered at 2605 Meridian Parkway, Suite 115, Durham, NC 27713. EmergingMed has chosen not to accept investments from trial sponsors to ensure that our services remain unbiased.
Letter from the CEO
Late one Sunday evening In January 1999, my husband called me on his cell phone from a taxi. He was seriously ill and on his way to the hospital.
The doctors were able to stabilize him temporarily, but they recommended additional surgery. My husband refused to undergo what would be a long,
difficult operation that would require months of recovery. I was obviously upset - not only about my husband's condition, but also about his apparent
unwillingness to accept the recommended treatment.
I was torn between the competing desires to respect his choices and to convince him to get treatment immediately. I began to search for treatment
options, mainly through the Internet, but found the information presented too simplistic, too scientific, or too voluminous. By chance, a friend
in California sent my husband an article about an alternative surgery at another hospital that had only recently been developed. This surgery was
being performed only a few miles from our home in New York City, yet we had never heard about it. My husband underwent this surgery, and seventeen years
later is still doing fine.
EmergingMed created its clinical trial matching and referral system to quickly and accurately connect patients with appropriate clinical trial options. We added personalized education and one-on-one support with Clinical Trial Navigators to help families make sense of these options, understand the narrow timeframes for joining a clinical trial, and identify and fix barriers that might otherwise interfere with a family's ability to seriously consider enrolling in a clinical trial.
No family should ever have to ask: "Why didn't anyone tell us?"
CEO and Founder, EmergingMed